Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Σάββατο 23 Δεκεμβρίου 2017

Lymphatic vessel involvement is predictive for lymph node metastasis and an important prognostic factor in endometrial cancer

Abstract

Background

Lymphovascular space involvement is reported to be an important risk factor in endometrial cancer. This study was conducted to evaluate the separate prognostic effects of lymphatic invasion and venous invasion on the outcomes of patients with endometrial cancer.

Methods

From 2006 to 2013, 189 histologically confirmed endometrial cancer patients were examined. To study the venous invasion (v) of the endometrial cancer, Victoria blue–H&E staining—which positively stains the elastic fibers of vessels—was performed. Immunohistochemical staining with D2-40 was used to study the lymphatic invasion (ly) of the endometrial cancer.

Results

The median age of the patients was 57 (range 25–84) years. ly(+) and/or v(+) patients were significantly more likely to present an advanced cancer stage, G3 tumor, and deep myometrial invasion than ly(−)/v(−) patients. The incidence of lymph node metastasis was high in ly(+) patients, and that of ovarian metastasis was high in v(+) patients. Lymphatic vessel invasion was significantly correlated with regional lymph node metastasis. We found a significantly higher incidence of distant metastasis in ly(+) patients. Most recurrences in ly(+)/v(−) patients occurred in lymph nodes, while those in ly(+)/v(+) patients occurred mainly at distant organs. Finally, the prognosis was significantly poorer for ly(+) patients, in whom lymphatic invasion was an independent prognostic factor along with distant metastasis.

Conclusions

Our study suggests that by separately evaluating lymphatic invasion and blood vessel invasion in endometrial cancer cases, useful information for predicting lymph node metastasis and recurrence sites as well as prognostic information can be obtained.



http://ift.tt/2zjttKS

Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery

88x31.png



http://ift.tt/2BDoqLh

Cancers, Vol. 10, Pages 3: Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells

Cancers, Vol. 10, Pages 3: Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells

Cancers doi: 10.3390/cancers10010003

Authors: Yoshiaki Sunami Artur Rebelo Jörg Kleeff

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer by 2030, and the overall 5-year survival rate is currently less than 7%. Cancer cells frequently exhibit reprogramming of their metabolic activity. It is increasingly recognized that aberrant de novo lipid synthesis and reprogrammed lipid metabolism are both associated with the development and progression of various cancers, including pancreatic cancer. In this review, the current knowledge about lipid metabolism and lipid droplets in pancreatic cancer is discussed. In the first part, molecular mechanisms of lipid metabolism and roles of enzymes involved in lipid metabolism which are relevant for pancreatic cancer research are presented. Further, preclinical studies and clinical trials with drugs/inhibitors targeting cancer metabolic systems in cancer are summarized. An increase of our knowledge in lipid metabolism in pancreatic cancer cells and in tumor stroma is important for developing novel strategies of future individualized therapies of pancreatic cancer.



http://ift.tt/2BpodqY

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313)

Abstract
Background
Homologous recombination deficiency (HRD) causing alterations have been reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD alterations might be more sensitive to anthracycline plus cyclophosphamide-based chemotherapy and report on HRD status and BRCA1 promoter methylation (PM) as prognostic markers in TNBC patients treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG9313.
Patients and Methods
425 TNBC patients were identified from S9313. HRD score, tumor BRCA1/2 sequencing and BRCA1 PM, were performed on DNA isolated from FFPE tissue. Positive HRD status was defined as either a deleterious tumor BRCA1/2 (tBRCA) mutation and/or a pre-defined HRD score ≥ 42. Markers were tested for prognostic value on DFS and OS using Cox regression models adjusted for treatment assignment and nodal status.
Results
HRD status was determined in 89% (379/425) of cases. Of these, 67% were HRD-positive (27% with tBRCA mutation, 40% tBRCA negative but HRD score ≥42). HRD-positive status was associated with a better DFS (HR = 0.72; 95% CI 0.51– 1.00; p=0.049) and non-significant trend towards better OS (HR = 0.71; 95% CI 0.48– 1.03; p=0.073). High HRD score (≥42) in tBRCA-negative patients (n=274) was also associated with better DFS (HR = 0.64; 95% CI 0.43-0.94; p=0.023) and OS (HR = 0.65; 95% CI 0.42-1.00; p=0.049). BRCA1 PM was evaluated successfully in 82% (348/425) and detected in 32% of cases. The DFS HR for BRCA1 PM was similar to that for HRD, but did not reach statistical significance (HR = 0.79; 95% CI 0.54-1.17; p=0.25).
Conclusions
HRD positivity was observed in two-thirds of TNBC patients receiving adjuvant AC and was associated with better DFS. HRD status may identify TNBC patients who receive greater benefit from AC based chemotherapy and should be evaluated further in prospective studies.
Clinical Trials Number
Int0137 (The trial pre-dates Clinicaltrial.Gov website establishment)

http://ift.tt/2DBgLdK

Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient

anti-PD-1liver transplantation

http://ift.tt/2phVe77

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials

Background
Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two Phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261).
Patients and methods
Patients with T790M-positive advanced NSCLC, who had progressed following prior epidermal growth factor receptor-tyrosine kinase inhibitor treatment, received osimertinib 80 mg once daily (n = 411). Patients with stable, asymptomatic CNS metastases were eligible for enrolment; prior CNS treatment was allowed. Patients with ≥1 measurable CNS lesion (per RECIST 1.1) on baseline brain scan by blinded independent central neuroradiology review (BICR) were included in the evaluable for CNS response set (cEFR). The primary outcome for this CNS analysis was CNS objective response rate (ORR) by BICR; secondary outcomes included CNS duration of response (DoR), disease control rate (DCR) and progression-free survival (PFS).
Results
Of 128 patients with CNS metastases on baseline brain scans, 50 were included in the cEFR. Confirmed CNS ORR and DCR were 54% (27/50; 95% confidence interval [CI] 39, 68), and 92% (46/50; 95% CI 81, 98), respectively. CNS response was observed regardless of prior radiotherapy to the brain. Median CNS DoR (22% maturity) was not reached (range: 1–15 months); at 9 months, 75% (95% CI 53, 88) of patients were estimated to remain in response. Median follow up for CNS PFS was 11 months; median CNS PFS was not reached (95% CI 7, not calculable). The safety profile observed in the cEFR was consistent with the overall patient population.
Conclusions
Osimertinib demonstrated clinically meaningful efficacy against CNS metastases, with a high DCR, encouraging ORR, and safety profile consistent with that previously reported.
ClinicalTrials.gov number
NCT01802632; NCT02094261

http://ift.tt/2phVdA5

Insulinoma-associated Protein 1 (INSM1) Differentiates Carcinoid Tumorlets of the Lung from Pulmonary Meningothelial-Like Nodules

Abstract

Insulinoma-associated protein 1 (INSM1) is a zinc-finger transcription factor isolated from pancreatic insulinoma tissue. This protein controls expression of a neuroendocrine phenotype and is responsible for transcription of synaptophysin and chromogranin. In recent years, it has emerged as a sensitive and specific immunohistochemical marker of neuroendocrine neoplasms, and is currently the only commercially available nuclear marker of neuroendocrine differentiation.

This article is protected by copyright. All rights reserved.



http://ift.tt/2BZzyl3